Internal medicine

Enzyme

Adverse effect

Dehydrogenase

Discontinuation

Fluorouracil

Thymidylate synthase

Oncology

Chemistry

Chemotherapy

Dihydropyrimidine dehydrogenase

Metabolism

Toxicity

Biochemistry

Medicine

Catabolism

Pharmacology

Cancers

Severe adverse events (toxicity) related to the use of the commonly used chemotherapeutic drug 5-fluorouracil (5-FU) affect one in three patients and are the primary reason cited for premature discontinuation of therapy. Deficiency of the 5-FU catabolic enzyme dihydropyrimidine dehydrogenase (DPD, encoded by

Testing for Dihydropyrimidine Dehydrogenase Deficiency to Individualize 5-Fluorouracil Therapy